peptide-affiliate-share
peptide-affiliate-share
The prediction
By 2026-12-31, peptide vendor affiliate revenue is less than 30 percent of total The Compound affiliate revenue (i.e., GLP-1 telehealth remains dominant revenue stream)
Math dominates: peptide affiliate CPA is 10-30x lower than GLP-1 affiliate CPA. Even if peptide traffic matches GLP-1 traffic, revenue share remains minority. Counter-narrative ~15%: PCAC grants Cat 1 (30% chance per prior forecast) + major US pharma launches approved peptide product with affiliate program + Compound pivots heavily. Resolves on The Compound internal Katalys + peptide network payout data. | OPERATOR 2026-04-23: Foundayo FDA-approved 2026-04-01; Hims listing it at $25/mo insurance / $149 cash — branded-GLP-1 economics more entrenched, marginally strengthens 0.85.
Trajectory
- 18 April 2026 · created85%signal strength 64
Math dominates: peptide affiliate CPA is 10-30x lower than GLP-1 affiliate CPA. Even if peptide traffic matches GLP-1 traffic, revenue share remains minority. Counter-narrative ~15%: PCAC grants Cat 1 (30% chance per prior forecast) + major US pharma launches approved peptide product with affiliate program + Compound pivots heavily. Resolves on The Compound internal Katalys + peptide network payout data. | OPERATOR 2026-04-23: Foundayo FDA-approved 2026-04-01; Hims listing it at $25/mo insurance / $149 cash — branded-GLP-1 economics more entrenched, marginally strengthens 0.85.
- 2026-04-22 04:04 UTC · Ra runread brief →85%0· signal 64
Math unchanged: GLP-1 affiliate CPA ($260) vs peptide ($8-40) dominates. No peptide DTC affiliate programs exist yet. Even if PCAC approves in July and Hims launches in H2, affiliate revenue would flow for only a few months. Augur notes GLP-1 compounding crackdown could shrink denominator, but GLP-1 Picks can shift to brand-name referrals.
Counter-narrativePCAC Cat 1 + major peptide DTC launch with high-CPA affiliate program could shift revenue mix, but timeline is too tight for 2026
- 2026-04-22 10:52 UTC · Ra runread brief →85%0· signal 64
Not covered by 15:30 run. FDA 30 additional warning letters (March 2026) accelerate GLP-1 compounding crackdown. Novo-Hims branded deal maintains GLP-1 referral revenue. No peptide DTC affiliate programs exist. Math unchanged.
Counter-narrativeGLP-1 compounding crackdown collapses affiliate denominator faster than expected while peptide programs emerge
- 2026-04-23 07:04 UTC · Ra runread brief →85%0· signal 64
Math unchanged. GLP-1 CPA $260 vs peptide $8-40 dominates. No peptide DTC affiliate programs exist. FDA 30 warning letters continue crackdown but Hims-Novo deal provides alternative.
Counter-narrativeGLP-1 compounding crackdown collapses affiliate denominator faster than branded deals replace it while peptide DTC with high CPAs emerges
- 2026-04-24 07:04 UTC · Ra runread brief →85%0· signal 64
Foundayo availability strengthens GLP-1 affiliate denominator. Branded oral GLP-1s at $149/mo provide alternative referral pathway as compounded GLP-1 crackdown continues. Math unchanged.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides by Q4
- 2026-04-25 07:04 UTC · Ra runread brief →85%0· signal 64
Foundayo oral launch creates additional branded GLP-1 referral pathway. GLP-1 CPA dominance unchanged. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-26 07:04 UTC · Ra runread brief →85%0· signal 64
FDA GLP-1 compounding crackdown continues (30 warning letters March 2026). Hims-Novo deal provides alternative branded revenue. No peptide DTC affiliate programs exist. Math unchanged.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-27 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review: GLP-1 CPA dominance ($260 vs $8-40) is structural. Foundayo and Hims-Novo deal strengthen branded GLP-1 referral pathways. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides by Q4
- 2026-04-28 04:04 UTC · Ra runread brief →85%0· signal 64
Foundayo slow launch reinforces branded GLP-1 revenue concentration on fewer products but does not change affiliate CPA math. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-29 07:04 UTC · Ra runread brief →85%0· signal 64
ACHIEVE-4 CV data strengthens branded GLP-1 physician confidence. Foundayo slow launch not a threat to affiliate math as GLP-1 CPA $260 vs peptide $8-40 dominates. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-30 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) is structural. Foundayo slow launch does not change math. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-01 07:04 UTC · Ra runread brief →85%0· signal 64
Foundayo retail availability broadens branded GLP-1 referral pathways. Analysts project 5-6M Rx in 2026. GLP-1 CPA dominance ($260 vs $8-40) structural. No peptide DTC affiliate programs. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-02 07:04 UTC · Ra runread brief →85%0· signal 64
FDA 503B GLP-1 exclusion entrenches branded GLP-1 revenue pathways. Hims-Novo deal and Foundayo availability maintain high CPA denominator. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-03 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) is structural. No peptide DTC affiliate programs exist. Foundayo and Hims-Novo deal maintain branded GLP-1 referral pathways. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-04 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema PDUFA ~October 2026 adds another branded referral pathway if approved. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-05 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-06 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema NDA filed adds another branded GLP-1 referral pathway if approved October 2026. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-07 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema PDUFA October 2026 adds another branded referral pathway. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-08 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Hims earnings Sunday may reveal peptide affiliate economics. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-09 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Hims Mon earnings = pre-call quiet. PeptideMaven confirms Hims peptide market entry but no affiliate-economics signal. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with $100+ CPA structurally comparable to GLP-1 referral economics
- 2026-05-10 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Tomorrow Hims earnings may reveal peptide distribution economics. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-11 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Hims earnings tonight may reveal peptide distribution economics. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-12 07:04 UTC · Ra runread brief →85%0· signal 64
Hims confirms no peptide affiliate program exists. "Not first to market" pushes any peptide revenue further out. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-13 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. Hims confirms no peptide affiliate program. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-14 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. No peptide DTC affiliate programs exist. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-15 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. No peptide DTC affiliate programs exist. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-16 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. No peptide DTC affiliate programs exist. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-17 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs surfaced. $300B market forecast does not change unit economics. GLP-1 CPA dominance structural. Holding.
Counter-narrativeIf Hims launches peptide DTC with $200+ CPA pricing analogous to GLP-1 economics, the math could invert faster than expected; current peptide CPA evidence remains $8-40 range
- 2026-05-18 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs surfaced. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeIf Hims launches peptide DTC with $200+ CPA analogous to GLP-1 economics the math could invert faster than expected
- 2026-05-19 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party Katalys payout collapsed $16 vs $1165 but ratio math unchanged. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-20 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. GLP-1 CPA dominance ($260 vs $8-40) structural. TRIUMPH-1 imminent readout extends branded GLP-1 pipeline timeline reinforcing denominator durability. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math
- 2026-05-21 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema NDA filed Dec 2025 PDUFA expected Q4 2026 or early 2027. Retatrutide TRIUMPH readouts 2026 with NDA possibly late 2026. Both deepen branded GLP-1 pipeline reinforcing CPA dominance. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math
- 2026-05-22 07:04 UTC · Ra runread brief →85%0· signal 64
TRIUMPH-1 retatrutide adds to branded GLP-1 pipeline (Foundayo live + retatrutide NDA expected late 2026 + CagriSema PDUFA Q4 2026). Each new branded GLP-1 reinforces CPA dominance ($260+ vs $8-40 peptide). No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math
- 2026-05-23 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $0 payout third consecutive week. GLP-1 CPA dominance ($260 vs $8-40) structural. Denominator approaching zero but forecast trivially holds when both numerator and denominator are zero. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-24 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $0 payout third consecutive week. GLP-1 CPA dominance ($260 vs $8-40) structural. Forecast trivially holds at zero-revenue base. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-26 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $0 payout fourth consecutive week. GLP-1 CPA dominance ($260 vs $8-40) structural. Forecast holds trivially at zero revenue base. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-27 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $400 payout (single Embody GLP-1 conversion) up from $0 prior 3 weeks. GLP-1 CPA dominance ($260 vs $8-40) structural. Forecast holds. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-28 07:04 UTC · Ra runread brief →85%0· signal 64
Retatrutide OA readout (71.2 lbs weight loss + OA pain relief) and CagriSema PDUFA ~October 2026 both deepen branded GLP-1 pipeline reinforcing CPA dominance. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-29 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party $400 payout single Embody conversion up from $16 prior week. GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema PDUFA Q4 2026 and retatrutide NDA extend branded pipeline moat. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-30 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA ~October 2026 and retatrutide NDA Q4 2026 extend branded GLP-1 pipeline moat. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-31 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Retatrutide TRIUMPH-1 30.3% weight loss and CagriSema PDUFA October 2026 deepen branded GLP-1 pipeline moat. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-01 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA confirmed ~October 2026 and retatrutide NDA expected late 2026 deepen branded GLP-1 pipeline moat. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- https://remypeptides.com/research/is-retatrutide-approved
- https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
- 2026-06-02 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Lilly ADA presentations June 5-8 deepen branded GLP-1 pipeline. CagriSema PDUFA October 2026 and retatrutide NDA expected late 2026. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-03 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. ADA data deepens branded GLP-1 pipeline moat. First-party glp1picks impressions +62% clicks +141% WoW — SEO recovery underway. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.biospace.com/press-releases/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-associations-86th-scientific-sessions-building-toward-a-new-era-of-choice-in-diabetes-and-obesity-care
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- https://valuesense.io/news/hims-lly-ceo-dudum-peptides-development-2026
- 2026-06-04 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Precision Peptide model is Rx-based not DTC-affiliate. ADA data deepens branded GLP-1 pipeline moat. First-party: glp1picks clicks +120% but $0 payout — click-to-conversion pipeline break not ratio-relevant. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-05 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. ADA data deepens branded GLP-1 pipeline to 7 distinct molecules — semaglutide tirzepatide orforglipron retatrutide CagriSema survodutide zenagamtide. Unprecedented pipeline depth reinforces GLP-1 CPA dominance. First-party: GSC impressions +14% WoW position 16.6 from 22.0 — SEO recovery continuing. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-associations-86th-scientific-sessions-building-toward-a-new-era-of-choice-in-diabetes-and-obesity-care-302783855.html
- https://www.biospace.com/press-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions
- https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement
- 2026-06-06 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. ADA Day 2: retatrutide TRIUMPH-1 presenting today and ACHIEVE-3 Lancet publication deepen branded GLP-1 pipeline to unprecedented depth. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-07 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. ADA deepened branded GLP-1 pipeline to 7 molecules. GLP-1 CPA dominance ($260 vs $8-40) structural. First-party GSC impressions -46% WoW clicks -63% position improved 19.6 to 16.7; Katalys $349. SEO recovery stalling. Stoic: ACTIONABLE continue diagnosis. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-knee-osteoarthritis-pain-and-obstructive-sleep-apnea-demonstrating-its-remarkable-potential-to-treat-obesity-and-its-complications-302793169.html
- https://www.biospace.com/drug-development/obesity-davids-and-goliaths-face-off-at-ada-2026
- https://www.peptidemaven.com/hims-hers-set-to-enter-the-peptide-market/
- 2026-06-08 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. OneTwenty is membership-model ($499) not CPA-based affiliate — does not change affiliate math. GLP-1 pipeline deepened to 7 molecules. First-party: Katalys clicks -27% WoW 1 conversion $349 Gala Health; GSC impressions -48% clicks -63% position 19.0 stable. Third consecutive decline week. GLP-1 CPA dominance ($260 vs $8-40) structural. Stoic: ACTIONABLE continue SEO diagnosis. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://onetwenty.com/blog/peptide-companies
- https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html
- https://www.peptidemaven.com/hims-hers-set-to-enter-the-peptide-market/
- 2026-06-09 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. OneTwenty is membership-model ($499) not CPA-based affiliate. First-party: Katalys $349 single Gala Health conversion clicks -51% WoW; GSC impressions -50% clicks -60% position 19.2. Fifth consecutive declining week. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://onetwenty.com/blog/peptide-companies
- https://www.cnbc.com/2026/06/08/novo-nordisk-eli-lilly-obesity-pills-medicare-coverage.html
- https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html
- 2026-06-10 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CVS Foundayo/Zepbound formulary additions provide additional branded GLP-1 referral pathways marginally strengthening denominator. OneTwenty membership-model ($499) not CPA-based. glp1picks traffic decline now sixth consecutive week concern — denominator thesis depends on SEO recovery. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-11 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. DOJ enforcement clearing gray-market vendors does not create affiliate programs. First-party: Katalys clicks -50% WoW 1 Gala Health conversion $349; GSC impressions -56% clicks -49% position 20.5 from 17.8. Seventh consecutive declining week. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-12 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys 209 clicks down 39% WoW 1 SkinnyRx conversion $500; GSC 1551 impressions down 58% 24 clicks down 49% position 18.6. Eighth consecutive declining week. SkinnyRx $500 drove 100% of weekly revenue — single-partner concentration. GLP-1 CPA dominance ($260-$500 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-13 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. OneTwenty $499/year membership model not CPA-based affiliate. Ninth consecutive declining week for glp1picks traffic but revenue per conversion remains high when conversions occur. GLP-1 CPA dominance ($260-$500 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-14 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. OneTwenty $499/year membership not CPA-based. GLP-1 pipeline depth grows (CagriSema filed retatrutide NDA expected MariTide Phase 3) entrenching branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. Tenth consecutive glp1picks traffic decline week but revenue per conversion high when conversions occur. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-15 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. GLP-1 pipeline deepening: CagriSema PDUFA Oct 2026 retatrutide NDA expected H2 2026 MariTide Phase 3 ongoing. Each new branded molecule entrenches $260+ CPA dominance. Eleventh consecutive glp1picks traffic decline week but CTR improved to 1.52% and Katalys clicks +6% WoW. SkinnyRx single-partner concentration ($500). Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html
- https://www.drugs.com/history/cagrisema.html
- 2026-06-16 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. OneTwenty $499/yr membership not CPA-based. First-party: Katalys clicks +64% WoW (318) 1 SkinnyRx conversion $500; GSC impressions -65% (1041) clicks -49% (19) CTR improved 1.83% position improved 17.4. Twelfth consecutive GSC decline week but Katalys click recovery suggests non-Google traffic resilience. CagriSema PDUFA late 2026 retatrutide NDA expected. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-17 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 315 +105% WoW 1 SkinnyRx conversion $500. GSC impressions 1028 -62% clicks 18 -47% CTR 1.75%. Thirteenth consecutive Google decline week but Katalys click doubling confirms non-Google channel compensation. Foundayo Week 7 11700 Rx Jefferies vs oral Wegovy 134000 weekly — branded GLP-1 revenue pool deepening. LegitScript peptide risk classification could restrict DTC peptide advertising further entrenching GLP-1 CPA dominance. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- https://pharmaphorum.com/news/lilly-falls-slower-start-foundayo-versus-wegovy
- https://www.fiercehealthcare.com/health-tech/hims-hers-expands-diagnostics-moves-canada-it-navigates-direct-consumer-prescription
- 2026-06-18 07:04 UTC · Ra runread brief →85%0· signal 64
Bloomberg gold rush and $100M gray-market validate peptide market exists but gray market bypasses traditional affiliate channels via crypto not CPA. No new peptide DTC affiliate programs in Katalys table. First-party: clicks 340 +101% WoW 1 SkinnyRx conversion $500. GSC impressions 1052 -60% clicks 14 -64%. Fourteenth consecutive GSC decline week but Katalys click recovery. Retatrutide NDA expected H2 2026 CagriSema PDUFA late 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-19 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 336 +89% WoW zero conversions $0 revenue. GSC impressions 1348 -44% clicks 22 -41% CTR 1.63% position 22.6. Fifteenth consecutive Google decline week. ECRI/ISMP warning and LegitScript risk classification may suppress peptide DTC advertising further entrenching GLP-1 CPA dominance. CagriSema PDUFA ~Oct 2026 retatrutide NDA Q4 2026 pipeline deepening. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://www.findhonestcare.com/metabolic-innovations/cagrisema/fda-timeline/
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- 2026-06-20 07:04 UTC · Ra runread brief →85%0· signal 64
Second consecutive zero-revenue Katalys week 405 clicks +94% WoW zero conversions $0. GSC 1804 impressions -12% 28 clicks -18% position 23.2. Fifteenth consecutive Google decline week. Katalys click recovery confirms non-Google channel compensation. No peptide DTC affiliate programs. CagriSema PDUFA late 2026 retatrutide NDA expected H2 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-21 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. Chainalysis $100M gray-market bypasses traditional affiliate channels via crypto not CPA. CagriSema PDUFA ~Oct 2026 retatrutide NDA expected Q4 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500. LegitScript peptide risk classification may cascade to ad platform policies restricting peptide DTC advertising. Sixteenth consecutive Google decline week. Stoic: not actionable — math structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-22 07:04 UTC · Ra runread brief →85%0· signal 64
Third consecutive $0-revenue Katalys week: 418 clicks +70% WoW zero conversions. GSC recovery continues: 2435 impressions +45% 40 clicks +38% but Embody-concentrated (top query embody tirzepatide reviews 224 impr). No peptide DTC affiliate programs. Retatrutide NDA expected Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-23 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Retatrutide NDA expected Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. No first-party Katalys or GSC data available this run. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-24 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 427 +34% WoW zero conversions $0 revenue fourth consecutive week. GSC impressions 2475 +43% clicks 47 +81% — organic recovery confirmed. Retatrutide NDA expected Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-25 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA ~Oct 2026 retatrutide NDA expected Q4 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. No first-party Katalys or GSC data this run. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-26 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Oral GLP-1 pipeline deepening: elecoglipron Phase 2b SOLSTICE 89.6% A1C target at ADA plus retatrutide NDA Q4 2026 plus CagriSema PDUFA Oct 2026. Three independent oral GLP-1 programs with clinical data entrench branded CPA dominance. $300B peptide market projection is hype not affiliate-program evidence. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-27 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 373 +11% WoW zero conversions $0 fifth consecutive week. GSC: impressions 1980 -11% clicks 37 -8% position 18.8 improved from 22.0 — organic recovery confirmed but Embody-concentrated. Retatrutide NDA Q4 2026 CagriSema PDUFA Oct 2026 pipeline deepening. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- https://remypeptides.com/research/is-cagrisema-approved
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-28 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Pipeline deepening: CagriSema NDA filed Dec 2025 FDA decision anticipated late 2026 or early 2027; retatrutide NDA expected Q4 2026 TRIUMPH-1 30.3% weight loss best-in-class. Three independent branded GLP-1 programs with advanced clinical data entrench $260-500 CPA dominance vs peptide $8-40. Math structurally unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-29 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA Oct 2026 retatrutide NDA Q4 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-500 vs peptide $8-40. Five consecutive weeks zero Katalys conversions flagged as denominator risk. Embody and replacement partners provide structural floor. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-30 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Retatrutide NDA expected Q4 2026 with TRIUMPH-1 30.3% weight loss; CagriSema NDA filed Dec 2025 PDUFA expected late 2026 or early 2027. Three independent branded GLP-1 programs entrench CPA dominance $260-500 vs peptide $8-40. MFN deal locks in branded pricing architecture. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-01 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Pipeline deepening: retatrutide NDA Q4 2026 TRIUMPH-1 30.3% weight loss; CagriSema NDA filed Dec 2025 confirmed by Novo Nordisk press release; three independent branded GLP-1 programs entrench CPA dominance $260-500 vs peptide $8-40. MFN deal locks branded pricing architecture. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-02 07:04 UTC · Ra runread brief →85%0· signal 64
Katalys breaks 5-week zero-conversion streak: 1 conversion $300 payout Trim Rx. GSC impressions 2136 -35% clicks 39 -39% position 21.4 Embody-concentrated. No peptide DTC affiliate programs. Retatrutide NDA Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-03 07:04 UTC · Ra runread brief →85%0· signal 64
Katalys: 1 conversion $300 Trim Rx 5-week zero-streak broken. GSC impressions 1832 -42% WoW clicks 33 -46% position 22.0. No peptide DTC affiliate programs. Pipeline deepening: retatrutide NDA Q4 2026 best-in-class 28.3% weight loss CagriSema under FDA review decision 2026. Three branded GLP-1 programs entrench CPA dominance $260-500 vs peptide $8-40. MFN deal locks branded pricing. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-04 07:04 UTC · Ra runread brief →85%0· signal 64
AstraZeneca elecoglipron enters Phase III on positive VISTA SOLSTICE IIb results up to 12% weight loss 36 weeks. Fourth oral GLP-1 program deepens pipeline. CagriSema PDUFA ~Oct 2026 retatrutide NDA Q4 2026. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Math reinforcing. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-05 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 586 +57% 2 conversions $600 payout recovery from 5-week zero streak. Trim Rx sole converter. GSC impressions 2875 clicks 51 position 20.6. Pipeline deepening continues. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-06 07:04 UTC · Ra runread brief →85%0· signal 64
First-party: Katalys $900 payout 3 conversions 625 clicks up 79% WoW from Trim Rx sole converter. GSC 3167 impressions up 11% 57 clicks up 10%. No peptide DTC affiliate programs. CagriSema possible approval unverified — if confirmed adds another branded GLP-1 widening denominator. Pipeline deepening AZ elecoglipron Phase III. Math reinforcing. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.astrazeneca.com/media-centre/press-releases/2026/elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme.html
- https://www.theplatinumcapital.com/article/novo-nordisk-cagrisema-fda-approval-weight-loss-drug-market-approaches-150bn
- https://www.glp1clinics.org/blog/cagrisema-diabetes-data-fda-decision-2026-06-13
- 2026-07-07 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs; Katalys clicks 388 with 1 Trim Rx conversion ($300) breaking five-week drought; GSC impressions 2133 (-32%) clicks 38 (-30%) position 20.6; CagriSema PDUFA ~Oct 2026 retatrutide NDA expected Q4 2026 — branded GLP-1 CPA dominance structural; holding 0.85
Counter-narrativeHims peptide launch (if triggered by PCAC Cat 1) could create CPA opportunities that break the branded-GLP-1-dominance thesis — but Hims affiliate terms historically favor owned channels over third-party publishers
- 2026-07-08 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema approval claim from Platinum Capital (May 2026) remains UNVERIFIED after 6+ weeks; standard NDA timeline (filed Dec 18 2025) points to PDUFA ~Oct 2026; if approved adds another $260+ CPA branded GLP-1 to denominator; retatrutide NDA Q4 2026; pipeline deepening continues; holding 0.85
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math; CagriSema approval adds another branded GLP-1 widening denominator
- https://www.theplatinumcapital.com/article/novo-nordisk-cagrisema-fda-approval-weight-loss-drug-market-approaches-150bn
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- 2026-07-10 07:04 UTC · Ra runread brief →85%0· signal 64
First-party: Katalys $2349 7 conv strongest week since Eden pause — Trim Rx $1200/4 Embody $800/2 Gala $349/1. GSC 4203 impressions +30% 83 clicks +54% position 17.5. CagriSema NOT approved PDUFA ~Oct 2026. Retatrutide NDA Q4 2026. Lilly biologic lawsuit remand does not change current math. No peptide DTC affiliates. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916470
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- https://endpoints.news/lilly-appeals-retatrutide-classification-ruling-in-case-that-could-impact-compounders/
- 2026-07-11 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema approval unverified — additional low-tier sources reference approval but no FDA.gov or Novo IR confirmation; standard NDA timeline PDUFA ~Oct 2026. Retatrutide NDA Q4 2026. No peptide DTC affiliates. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.fiercepharma.com/pharma/if-thats-not-acceleration-i-dont-know-what-novo-nordisk-ceo-doustdar-talks-leadership-new
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- https://endpoints.news/lilly-appeals-retatrutide-classification-ruling-in-case-that-could-impact-compounders/
- 2026-07-12 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema CONFIRMED approved May 2026 per Drugs.com Tier 1 history page. Adds $260+ CPA branded GLP-1 to denominator. First-party Katalys $2049/6conv week. GSC 4052 impr +4% 83 clicks +20% position 15.0. Zero peptide DTC affiliates. Structural dominance reinforced. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- https://www.drugs.com/history/cagrisema.html
- https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- 2026-07-13 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema approval claim from July 12 under RE-VERIFICATION — multiple Tier 1 sources (Ro CNBC GLP1Clinics BioPharma-PEG) describe as pending FDA decision. Retatrutide NDA Q4 2026. No peptide DTC affiliates. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-14 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema verification complete NOT approved NDA filed Dec 2025 decision expected late 2026. Drugs.com history page misinterpreted July 12 tracks filing milestones not approvals. First-party Katalys $2049 6conv all GLP-1 partners zero peptide DTC. Structural dominance intact. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-15 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys $1649/5conv week. GSC 5864 impr +23% 127 clicks +59% position 13.7. Zero peptide DTC affiliates. Retatrutide NDA Q4 2026 Lilly biologic appeal ongoing. CagriSema NDA pending not approved. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-16 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys $600/2conv week all Trim Rx. GSC 4891 impr -8% 99 clicks +1% position 13.5. Zero peptide DTC affiliates. CagriSema NDA pending not approved day 4 misinformation. Retatrutide NDA Q4 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-17 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys $300/1conv Trim Rx sole converter down from $600/2conv. GSC 6242 impr +7% 119 clicks +3% position 13.0 improved from 16.7. Zero peptide DTC affiliates. CagriSema NOT approved NDA pending per Ro.co. Retatrutide NDA Q4 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-18 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema NDA pending NOT approved decision expected late 2026. Retatrutide NDA Q4 2026 Lilly biologic appeal remanded ongoing. Zero peptide DTC affiliates. GLP-1 CPA dominance $260-500 vs peptide $0 structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-19 07:04 UTC · Ra runread brief →85%0· signal 64
Retatrutide NDA Q4 2026. CagriSema NDA pending NOT approved decision late 2026. Zero peptide DTC affiliates in Katalys network. First-party Katalys $300/1conv. GLP-1 CPA dominance $260-500 vs peptide $0 structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-20 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys 0 conversions / $0 this week (clicks +11%, GSC impressions -44%) — reads as attribution lag / traffic volatility, not a thesis change; still zero peptide DTC affiliates in network. FDA staff proposing against all 7 peptides further delays any compliant peptide affiliate surface. GLP-1 CPA dominance structural. Holding.
Counter-narrativeA Cat 1 grant plus a Hims/peptide DTC affiliate launch could build peptide affiliate revenue, but neither exists yet
- morning-sources/first-party-pulse.md 2026-07-19 (Katalys 7d + GSC 7d)
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- 2026-07-21 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys this week 1 conversion / $300 payout (prior $2,049), clicks +12%, GSC impressions -47% w/w — soft-revenue week, reads as single-provider (embody-cluster) lumpiness, not a thesis change. Still zero peptide DTC affiliates in network. GLP-1 CPA dominance ($260-500 vs peptide $0) structural. Holding.
Counter-narrativeA surprise Cat 1 grant Wednesday plus a Hims/peptide DTC affiliate launch could begin building peptide affiliate revenue, but neither exists yet
- morning-sources/first-party-pulse.md 2026-07-20 (Katalys 7d + GSC 7d)
- https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr
- 2026-07-22 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys 1 conversion / $300 payout (Trim Rx), clicks +7%, GSC impressions -20% w/w — soft revenue week reading as single-provider lumpiness, not a thesis change. Zero peptide DTC affiliates in the Katalys network; staff-against-all-7 further delays any compliant peptide affiliate surface. GLP-1 CPA dominance structural. Holding.
Counter-narrativeA surprise Cat 1 grant Wednesday plus a Hims/peptide DTC affiliate launch could begin building peptide affiliate revenue toward 30%+, but neither exists yet.
- morning-sources/first-party-pulse.md 2026-07-21 (Katalys 7d + GSC 7d)
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-23 04:05 UTC · Ra runread brief →85%0· signal 64
First-party Katalys 2 conv/$450 payout this week (prior $1,649), clicks -8%, GSC impressions -32% w/w — soft-revenue week reading as conversion lumpiness (Trim Rx $300, Embody $150), not a thesis change. Zero peptide DTC affiliates in network; a less-conflicted panel likely voting no further delays any compliant peptide affiliate surface. GLP-1 CPA dominance ($260-500 vs peptide $0) structural. Holding.
Counter-narrativeA surprise Cat 1 grant today plus a Hims/peptide DTC affiliate launch could begin building peptide affiliate revenue toward 30%, but neither exists yet.
- morning-sources/first-party-pulse.md 2026-07-22 (Katalys 7d + GSC 7d)
- https://news.bloomberglaw.com/health-law-and-business/fda-adds-more-peptide-panel-experts-after-conflict-criticism
- 2026-07-24 04:04 UTC · Ra runread brief →83%-0.02· signal 66
Counter-narrative's first leg (Cat-1 recommendation) materialized, but advisory-only + no legal compounding pathway in 2026 + zero Katalys peptide providers + CPA math keep GLP-1 dominant; token -0.02 to 0.83.
Counter-narrativeA Cat-1 recommendation plus a Hims peptide DTC affiliate launch could begin building peptide revenue toward 30%, but neither a legal compounding pathway nor a Katalys peptide provider exists in 2026.
- 2026-07-25 04:04 UTC · Ra runread brief →83%0· signal 66
First-party Katalys this week $600 payout / 3 conv (prior $300), clicks +185% -- 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners; GSC impressions +57% entirely Embody/tirzepatide queries. The 8-12mo Cat-1 rulemaking timeline delays any compliant peptide affiliate surface past 2026. CPA math ($260-500 GLP-1 vs $0 peptide) structural. Holding.
Counter-narrativeA Hims/peptide DTC affiliate launch after rulemaking could begin building peptide revenue toward 30%, but no legal compounding pathway or Katalys peptide provider exists in 2026.
- morning-sources/first-party-pulse.md 2026-07-24 (Katalys 7d + GSC 7d)
- https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
- 2026-07-26 04:04 UTC · Ra runread brief →83%0· signal 66
Held. First-party pulse: Katalys $600/3 conv, 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners. New DTC peptide entrants (Precision Peptide, PepScribe, Ascend Vitality) are an emerging 2027 threat, not 2026: no legal compounding pathway (8-12mo rulemaking) and no Katalys peptide provider today. CPA math structural.
Counter-narrativeA wave of new peptide telehealth DTC platforms could seed a peptide affiliate surface; if one joins Katalys at telehealth-grade CPA the >30% flip becomes reachable, but not in 2026.
- morning-sources/first-party-pulse.md 2026-07-25 (Katalys 7d $600, 100% GLP-1)
- https://www.newsfilecorp.com/release/304286/
- https://fortune.com/2026/07/20/the-fda-peptide-vote-could-create-telehealths-next-multibillion-dollar-market-telehealth-hims-ro-glp1-ozempic-injectables/
- 2026-07-27 04:15 UTC · Ra runread brief →83%0· signal 66
Held. First-party Katalys 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners; 503A Category-1 rulemaking confirmed 12-18mo from the July vote (Orrick), delaying any compliant peptide affiliate surface past 2026. CPA math ($260-500 GLP-1 vs $0 peptide) structural.
Counter-narrativeA peptide DTC platform joining Katalys at telehealth-grade CPA after rulemaking could push peptide revenue toward 30%, but no legal compounding pathway or Katalys peptide provider exists in 2026.
- morning-sources/first-party-pulse.md 2026-07-26 (Katalys 7d $600/3 conv, 100% GLP-1)
- https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting
- 2026-07-28 04:05 UTC · Ra runread brief →83%0· signal 66
Held 0.83. First-party Katalys this week $300/2 conv, 100% GLP-1 (Embody), zero peptide DTC partners; clicks +218% w/w all GLP-1. 12-18mo Cat-1 rulemaking delays any compliant peptide affiliate surface past 2026. CPA math ($260-500 GLP-1 vs $0 in-network peptide) structural.
Counter-narrativeA peptide DTC platform joining Katalys at telehealth-grade CPA after rulemaking could push peptide revenue toward 30%, but no legal compounding pathway or Katalys peptide provider exists in 2026.
- morning-sources/first-party-pulse.md 2026-07-27 (Katalys 7d $300/2 conv, 100% GLP-1 Embody; clicks +218%)
- https://seekingalpha.com/news/4617588-hims-hers-gains-fda-panel-endorses-peptide-bpc-157
- 2026-07-29 04:20 UTC · Ra runread brief →83%0· signal 66
Held 0.83. Source pack is one day stale (07-28 window): Katalys $600 on 4 conversions, 100% GLP-1 via Embody at $6.12 EPC while eight other partners sit at $0 -- revenue concentration, zero peptide DTC partners. New consideration logged: FDA is reassessing the DSHEA 'dietary substance' definition with peptides near the centre (NutraIngredients Jul 27), a route that bypasses 503A rulemaking entirely; it does not move the forecast because supplement AOV commissions are 10-30x below GLP-1 telehealth CPA and would need enormous volume to reach 30%.
Counter-narrativeAn oral peptide sold under the supplement framework needs no compounding pathway and could carry affiliate commissions in 2026 without waiting on rulemaking, but supplement-grade commissions are the exact low-CPA problem this forecast is built on.
- morning-sources/first-party-pulse.md 2026-07-28 (Katalys 7d $600/4 conv, 100% GLP-1 Embody, EPC $6.12; eight partners at $0)
- https://www.nutraingredients.com/Article/2026/07/27/fda-peptide-panel-raises-questions-about-future-dietary-supplement-pathway/
- 2026-07-30 04:10 UTC · Ra runread brief →85%+0.02· signal 68
Nudged 0.83->0.85 on door-counting rather than new volume. Three of four routes to a 2026 peptide affiliate surface are now demonstrably closed with five months left: (1) legal 503A compounding needs an NPRM plus notice-and-comment plus final rule, 12-18mo per Orrick; (2) the research-use-only gray-market vendor channel -- the one route that needed no rulemaking and could have carried commissions today -- is under active FDA enforcement, seven warning letters dated Mar 31 2026 with bacteriostatic-water bundling read as injection intent and RUO disclaimers held irrelevant; (3) the DSHEA dietary-substance route is under reassessment only, no proposed rule, and carries supplement-grade commissions that are the low-CPA problem this forecast is built on. Fourth route, an existing DTC platform joining Katalys, remains open and is the live falsifier. First-party: Katalys $450 on 3 conversions, 100% Embody at $4.64 EPC (down from $6.12 w/w) with eight partners at exactly $0 -- zero peptide partners, and a revenue-concentration fragility in the denominator this forecast is measured against.
Counter-narrativeA 503A peptide telehealth platform joining Katalys at telehealth-grade CPA before Dec 31 would start building peptide revenue toward 30%, and the live DTC entrants prove the channel does not wait for rulemaking.
- morning-sources/first-party-pulse.md 2026-07-29 (Katalys 7d $450/3 conv, 100% GLP-1 Embody EPC $4.64; eight partners at $0)
- https://policycanary.io/blog/fda-research-peptide-warning-letters-april-2026
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://www.restorehealthconsulting.com/news/fda-peptides-meeting-july-2026-what-happens-after-the-pcac-vote
- 2026-07-31 04:15 UTC · Ra runread brief →85%0· signal 69
HELD ON PURPOSE at 0.85. Yesterday raised this to 0.85 on a door-count; today the Federal Register confirms at primary source that the legal-compounding door is not merely slow but has not opened at all, and that the 503B comment period on FDA proposal to EXCLUDE semaglutide, tirzepatide and liraglutide closed 2026-07-30 under docket FDA-2018-N-3240, which if finalized protects the branded-GLP-1 economics that are this forecast denominator. Both point the same way as yesterday. Confirming an insight is not repricing it - that is the rule this council wrote on 2026-07-30 and today is its first application. First-party: $450 on 3 conversions, 100% Embody, EPC $5.70, zero peptide partners.
Counter-narrativeA 503A peptide telehealth platform joining Katalys at telehealth-grade CPA before Dec 31 remains the live falsifier, and Precision Peptide and PepScribe are already operating nationwide without one.
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal (Docket FDA-2018-N-3240, comments closed 2026-07-30)
- https://www.federalregister.gov/api/v1/documents.json?conditions[term]=%22bulk+drug+substances%22&conditions[publication_date][gte]=2026-06-01
- morning-sources/first-party-pulse.md 2026-07-30 (Katalys 7d $450/3 conv, 100% GLP-1 Embody, EPC $5.70, eight partners at $0)
- 2026-08-01 04:12 UTC · Ra runread brief →85%0· signal 70
Held 0.85. Zero bulk-drug-substances documents since July 1 means no legal 503A supply exists to hang an affiliate programme on in the five months remaining, and the major networks will not onboard pre-rulemaking gray-market vendors. Confirming an insight is not repricing it, per the rule this council wrote on 2026-07-30. The uncomfortable first-party reading is that this forecast is surviving partly on denominator decay: Katalys payout fell $450 to $300 while clicks rose 45 percent, and GSC impressions fell 20 percent. A ratio forecast stays true when its numerator is zero regardless of what the denominator does, so it is becoming less informative about the thing that actually matters. Routed to the strategic memo rather than repriced. Signal strength 69 to 70.
Counter-narrativeLeerink's $2.2B peptide telehealth market is the sharpest version yet of the case that a peptide affiliate programme at telehealth-grade CPA appears before Dec 31, and Precision Peptide and PepScribe already operate nationwide without one.
- morning-sources/first-party-pulse.md 2026-07-31 (Katalys 7d $300 on 2 conversions, clicks 1047 up 45 percent, 100 percent Embody GLP-1, EPC $5.36, eight partners at $0, zero peptide partners)
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=%22bulk%20drug%20substances%22&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-01 (count 0)
- https://www.morningstar.com/company-reports/1489820-hims-hers-health-favorable-decision-on-peptides-lifts-investor-appetite-but-uncertainty-very-high
- 2026-08-02 04:15 UTC · Ra runread brief →83%-0.02· signal 72
Lowered for the first time in six runs, and the reason is specific rather than decay. The council's named falsifier has been a 503A peptide telehealth platform reaching affiliate-network standards before Dec 31. LegitScript merchant certification is precisely that standard and one such platform now holds it, so the falsifier moved from hypothetical to structurally available. The CPA arithmetic still dominates, hence -0.02 and not more. First-party pulse also reverses last week's decline read: payout $600 to $900 on 67 percent more conversions.
Counter-narrativePeptide affiliate CPA is 10-30x below GLP-1 telehealth CPA, so even a signed peptide partner needs an order of magnitude more conversions to reach 30 percent of revenue in five months, and Compound currently has zero.
- https://www.newsfilecorp.com/release/305900/The-Precision-Peptide-Company-Activates-Nationwide-DirecttoConsumer-Peptide-Sales-with-Retail-Telehealth-Website-Launch (LegitScript Healthcare Merchant Certification 2026-06-23, the gate affiliate networks and ad platforms underwrite against)
- morning-sources/first-party-pulse.md 2026-08-01 (Katalys 7d payout $900 up from $600, 5 conversions up 67 percent, clicks 1171 down 19 percent, Embody GLP-1 EPC $8.33, zero peptide partners)
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=%22bulk+drug+substances%22&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-01 (count 0)
- 2026-08-03 04:15 UTC · Ra runread brief →77%-0.06· signal 78
Lowered 0.06, the largest move on this row since inception, and the reason is that the Historian's eight-run-old arithmetic was built on the wrong monetization model. The forecast's own sources field prices peptide affiliate revenue as vendor commissions of 10-20 percent on $80-200 AOV, or $8-40 a sale, against a $260 Katalys GLP-1 CPA - the 10-30x gap. The market did not go that way. Live Vital, Telos Rx, Strut and Bodybuilding Health+ are recurring telehealth subscriptions at $66-116/mo, the same economic shape as GLP-1 telehealth, roughly 2-4x below the GLP-1 CPA rather than 10-30x. A competing publisher with 1007 referring domains is already taking commission on them. The denominator cuts the same way: Katalys is running $900 a week, so 30 percent is a small absolute number. Not moved further because Compound has signed nobody.
Counter-narrativeCompound has zero peptide affiliate partners signed with five months to run, bestpeptideforthat deliberately carries no gray-market vendor revenue and its Katalys application is still pending, so the operational path to 30 percent of revenue by Dec 31 remains unbuilt whatever the unit economics now look like.
- https://healingmaps.com/peptide-telehealth/ (HTTP 200, updated 2026-07-28, explicit affiliate disclosure and a named Editorial Partner deal with Live Vital; four peptide telehealth programs monetized at $66-116/mo recurring subscription pricing)
- DataForSEO Labs keyword_overview via seo-lookup.yml run 30783805520, 10 keywords, $0.0368: peptide telehealth 170/mo KD 0 CPC $12.25; peptide therapy online 110/mo KD 0 CPC $11.23; peptide clinic online 30/mo KD 0 CPC $14.81; bpc-157 online prescription 30/mo CPC $4.15 transactional; no volume data for bpc 157 prescription and where to buy bpc-157
- DataForSEO backlinks summary same run: healingmaps.com rank 248, 2900 backlinks from 1007 referring domains, first seen 2021-01-16
- morning-sources/first-party-pulse.md 2026-08-02 pack (Katalys 7d payout $900, 5 conversions, zero peptide partners)
- 2026-08-04 04:15 UTC · Ra runread brief →78%+0.01· signal 80
Raised 0.01, and for the first time on this row the mover is the first-party pulse rather than the news. This forecast is a ratio and the denominator jumped: Katalys 7d payout went $600 to $1,350 on 8 conversions against 3, so 30 percent of total became a larger absolute number in a week while the peptide numerator stayed at exactly zero signed partners. Against that, the category breadth cuts the other way - six named platforms at $66-199/mo recurring, up from four yesterday. Offsetting, net small and up. Concentration worth flagging: Embody GLP1 is 78 percent of the payout, so the denominator this forecast now leans on rests on one partner.
Counter-narrativeCompound has zero peptide affiliate partners signed with five months to run, bestpeptideforthat deliberately carries no gray-market vendor revenue and its Katalys application is still pending, so the operational path to 30 percent of revenue by Dec 31 remains unbuilt whatever the unit economics now look like.
- morning-sources/first-party-pulse.md 2026-08-03 pack, window 2026-07-27 to 2026-08-03: Katalys 7d payout $1,350 against $600 prior (+$750), 8 conversions against 3 (+167 percent), on 1,090 clicks (-31 percent); Embody GLP1 alone is $1,050 of the $1,350 on 7 conversions at $12.35 EPC; zero peptide partners in the table
- https://www.openpr.com/news/4588018/top-online-peptide-recovery-clinics-of-2026-rebody-health-leads (agent-fetch run 30877028979, HTTP 200: six peptide telehealth platforms at $66-$199/mo recurring, and the ranking is an ABNewswire paid release written by its own winner, syndicated to openPR and regional news shells)
- seo-lookup.yml run 30877035059, DataForSEO Labs keyword_overview, 8 keywords, $0.0127
- 2026-08-05 04:15 UTC · Ra runread brief →82%+0.04· signal 83
Reversing three runs of drift toward the peptide side, on the denominator rather than the news. Payout went 5x week over week on GLP-1 alone, conversions 2 to 9, while the peptide numerator stayed at zero signed partners for an eleventh pack. And today's legal verification caps how fast the numerator can move at all: with compounding still unlawful for the class, a compliant US peptide affiliate programme has nothing to pay a commission on inside the 148 days left. Concentration flag persists and worsens - Embody GLP1 is $1,200 of $1,500, 80 percent of the denominator on one partner.
Counter-narrativeA single Katalys week is noisy and 929 clicks at -46 percent is a shrinking top of funnel; if GLP-1 traffic keeps decaying while peptide search compounds, the ratio closes from the denominator side rather than the numerator side, which is the path this forecast is least able to see.
- morning-sources/first-party-pulse.md 2026-08-04 pack, window 2026-07-28 to 2026-08-04: Katalys 7d payout $1,500 against $300 prior, 9 conversions against 2, on 929 clicks (-46 percent); Embody GLP1 alone is $1,200 of the $1,500 on 8 conversions at $11.88 EPC; zero peptide partners in the table for the eleventh consecutive pack
- https://www.npr.org/2026/08/03/nx-s1-5913381/health-fda-peptides-product-regulation (agent-fetch run 30974432502, HTTP 200: US pharmacies still may not lawfully compound the peptide class, so a compliant peptide affiliate programme has no product to pay on before the rulemaking lands)
- DataForSEO Labs keyword_overview via seo-lookup.yml run 30974448178, 12 keywords, $0.0130: 'are peptides legal' 8,100/mo KD 0 CPC $19.34, informational
- 2026-08-06 04:15 UTC · Ra runread brief →85%+0.03· signal 86
Payout more than tripled week on week on a 45 percent click decline, which is a conversion-quality move rather than a traffic move. The peptide numerator stays at zero for a twelfth pack and today's Federal Register check caps it independently: with no rulemaking notice on file there is no compliant US peptide affiliate programme to pay on inside 147 days, and today's 70-month sentence raises the cost of the non-compliant kind. Concentration risk is now the live threat to this row and it points the wrong way.
Counter-narrativeThe numerator is capped but the denominator is not safe: Embody GLP1 is 84.6 percent of this week's payout, and if that single partner churned a small peptide numerator could clear 30 percent arithmetically without any peptide growth at all.
- morning-sources/first-party-pulse.md 2026-08-05 pack, window 2026-07-29 to 2026-08-05: Katalys 7d payout $1,950 against $600 prior, 12 conversions against 4, on 1,017 clicks (-45 percent); Embody GLP1 alone is $1,650 of the $1,950 on 11 conversions at $13.52 EPC; zero peptide partners in the table for the twelfth consecutive pack; GSC average position 7.9 against 10.0 prior on impressions -29 percent and clicks -31 percent
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=bulk+drug+substances&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-01&order=newest (agent-fetch run 31070681710, HTTP 200, count 16, no 503A bulks-list rulemaking)
- https://efts.sec.gov/LATEST/search-index?q=%22Foundayo%22&forms=8-K (agent-fetch run 31070744390, HTTP 200: Lilly 8-K accession 0000059478-26-000077, EX-99.1, file_date 2026-08-05, items 2.02 and 9.01)
- 2026-08-07 04:15 UTC · Ra runread brief →86%+0.01· signal 87
Federal Register caps the numerator structurally while the pack shows the denominator concentrating further, which pushes the two halves of this forecast in opposite directions; net +0.01 rather than the +0.03 the numerator evidence alone would justify.
Counter-narrativeThe risk has never been the peptide numerator and it is worse today than yesterday: a single partner is now 85.7 percent of payout, so if Embody GLP1 churned, a small peptide numerator could clear 30 percent arithmetically without any peptide growth at all.
- morning-sources/first-party-pulse.md 2026-08-06 pack, window 2026-07-30 to 2026-08-06: Katalys 7d payout $2,100 against $450 prior, 13 conversions against 3, on 1,068 clicks (-45 percent); Embody GLP1 alone is $1,800 of the $2,100 on 12 conversions at $13.33 EPC, which is 85.7 percent of payout against 84.6 percent in the prior pack; zero peptide partners in the table for the thirteenth consecutive pack; GSC average position 7.2 against 10.0 prior on impressions -2 percent and clicks -7 percent
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=bulk+drug+substances&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-23&order=newest (agent-fetch run 31146638435, HTTP 200: no 503A bulks-list rulemaking, so no compliant US peptide affiliate programme can exist inside the horizon)
- 2026-08-08 04:15 UTC · Ra runread brief →87%+0.01· signal 88
Fourteenth consecutive pack with a zero peptide numerator, and the structural cap held again at primary source - nothing is legally compoundable at day 16, so no US peptide vendor can underwrite an affiliate program to an ad-network standard. +0.01. The concentration worsened again, 88.2 percent from 85.7 percent, on 42 percent fewer clicks converting four times better, which is the same warning as yesterday one notch louder.
Counter-narrativeThe denominator is the risk, not the numerator: a single partner is now 88.2 percent of payout, so one affiliate program change could shrink total revenue far faster than any peptide line could grow into it, and the ratio could clear 30 percent without a peptide dollar being earned.
- morning-sources/first-party-pulse.md 2026-08-07 pack, window 2026-07-31 to 2026-08-07: Katalys 7d payout $2,550 against $450 prior, 16 conversions against 3, on 980 clicks (-42 percent); Embody GLP1 alone is $2,250 of the $2,550 on 15 conversions at $16.67 EPC, which is 88.2 percent of payout against 85.7 percent in the prior pack; zero peptide partners in the table for the fourteenth consecutive pack; GSC average position 7.0 against 9.9 prior on impressions -14 percent and clicks -20 percent
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=bulk+drug+substances&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-23&order=newest (agent-fetch run 31238811859, HTTP 200, count 4, no 503A bulks-list rulemaking at day 16)
- 2026-08-09 04:18 UTC · Ra runread brief →88%+0.01· signal 88
+0.01, and unlike the two rows I froze today the time decay here is real evidence rather than a repeated constant: this forecast needs a three-stage chain inside 144 days - the substances become lawfully compoundable, a vendor launches an affiliate programme, and it scales to 30 percent of Compound revenue - and stage one is verified not started. Contrast hims-peptide-launch, which needs only a single announcement Hims has historically made without waiting for legality, which is why that row is frozen and this one still moves. The sharpening today is that the demand side is as concentrated as the revenue side, which is a portfolio finding rather than a forecast finding and is carried to the strategic memo.
Counter-narrativeThe denominator is the whole risk and it is now visible on both sides of the funnel: one partner is 87.3 percent of payout AND every one of the fifteen top queries is that partner's brand, so if Embody churned or de-indexed, a small peptide numerator could clear 30 percent arithmetically without a peptide dollar being earned.
- morning-sources/first-party-pulse.md 2026-08-08 pack, window 2026-08-01 to 2026-08-08: Katalys 7d payout $2,749 against $300 prior, 17 conversions against 2, on 795 clicks (-24 percent); Embody GLP1 alone is $2,400 of the $2,749 on 16 conversions at $18.46 EPC, which is 87.3 percent of payout against 88.2 percent in the prior pack; zero peptide partners in the table for the FIFTEENTH consecutive pack; GSC impressions 15,911 (-19 percent), clicks 255 (-24 percent), average position 7.0 against 9.4 prior
- NEW READ of the same pack: all 15 rows of the top-query table contain the token 'embody', and /reviews/embody alone is 10,817 of 15,911 impressions, so the concentration is in demand and not only in payout
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=bulk+drug+substances&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-23&order=newest (agent-fetch run 31294014846, HTTP 200, count 4, no 503A bulks-list rulemaking at day 17, so no compliant US peptide affiliate programme can exist inside the remaining 144 days)
- 2026-08-10 04:15 UTC · Ra runread brief →89%+0.01· signal 89
+0.01, and for once the increment is a mechanism rather than a day burned. This needs a three-stage chain inside 143 days - substances become lawfully compoundable, a vendor launches an affiliate programme, it reaches 30 percent of Compound affiliate revenue - and NPR gives the first primary-sourced number on the gap between stage one and stage two: two to nine months for pharmacies to acquire active ingredients after any green light. Even the fast interim path NPR describes puts stage two in 2027. Offsetting that, the denominator risk strengthened. One correction to yesterday's brief: fourteen of the top fifteen GSC queries carry Embody's brand, not fifteen - gala tirzepatide at 62 impressions does not.
Counter-narrativeThe denominator is the whole risk and it got worse today, not better: Embody is now 88.6 percent of payout against 87.3 percent a pack ago, so the single event that resolves this FALSE is not peptide revenue growing but GLP-1 revenue collapsing.
- morning-sources/first-party-pulse.md 2026-08-09 pack, window 2026-08-02 to 2026-08-09: Katalys 7d payout $3,049 against $900 prior, 19 conversions against 5, on 718 clicks (-39 percent); Embody GLP1 alone is $2,700 of the $3,049 on 18 conversions at $20.61 EPC, which is 88.6 percent of payout against 87.3 percent in the prior pack; zero peptide partners for a sixteenth consecutive pack
- https://www.npr.org/2026/08/03/nx-s1-5913381/health-fda-peptides-product-regulation (agent-fetch run 31354740154, HTTP 200: Scott Brunner of the Alliance for Pharmacy Compounding on post-approval supply, it might take two months, it might take nine months, it depends on the substance)
- 2026-08-11 04:16 UTC · Ra runread brief →89%0· signal 89
Held at 0.89, delta 0, and the hold is deliberate. The reflex was +0.01 for the third day running on the same mechanism, concentration up and the legal precondition still unmet. I declined it, because the counter-case strengthened on the same day by roughly the same amount: a 49 percent click collapse against a 320 percent conversion rise is a funnel getting narrower and better at once, and narrow-and-converting is the fragile shape. Two offsetting moves net to zero, and a ritual increment would have been anchoring dressed as Bayesian work.
Counter-narrativeThe denominator is the whole risk and today it moved BOTH ways: Embody concentration rose to 89.6 percent of payout, but clicks fell 49 percent and GSC clicks 23 percent, so the funnel that produces the GLP-1 denominator is thinning even as it converts better - and the single event that resolves this FALSE is not peptide revenue growing but GLP-1 revenue collapsing.
- morning-sources/first-party-pulse.md 2026-08-10 pack, window 2026-08-03 to 2026-08-10 (ONE DAY STALE, today's 04:00 aggregation had not committed at run time): Katalys 7d payout $3,349 against $900 prior, 21 conversions against 5, on 582 clicks which is -49 percent; Embody GLP1 alone is $3,000 of the $3,349 on 20 conversions at $22.39 EPC, which is 89.6 percent of payout against 88.6 percent in the prior pack; zero peptide partners in the table for the SEVENTEENTH consecutive pack; GSC impressions 19,539 (-7 percent), clicks 278 (-23 percent), average position 6.9 against 8.9 prior
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=bulk+drug+substances&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-23&order=newest (agent-fetch run 31457706167, HTTP 200, count 4, day 19, so the first link in the three-stage chain is still unmade with 142 days left)
- 2026-08-12 04:15 UTC · Ra runread brief →91%+0.02· signal 90
Took +0.02 after declining +0.01 yesterday, and the difference is the size of the measured move. Katalys payout stepped from $1,350 to $3,499 (+159%) on clicks down 46%, so GLP-1 revenue did not merely hold, it more than doubled. Embody is 90.0% of payout at EPC $23.68. Zero peptide partners for an 18th consecutive pack, and with 141 days to horizon a peptide network would have to be signed, integrated and scaled past 30% of payout from a standing start of zero.
Counter-narrativePayout +159% rests on 22 conversions and one partner at 90% of the total, while clicks fell 46% and GSC clicks 30%; a denominator that collapses is what lets a minority numerator cross 30%, and that risk is unchanged.
- morning-sources/first-party-pulse.md 2026-08-11 (proprietary, window 2026-08-04 to 2026-08-11)
- 2026-08-13 04:15 UTC · Ra runread brief →91%0· signal 90
Declined the move. Payout $3,398 against $1,500 prior, conversions 20 (+122%) on clicks 552 (-41%). Embody fell 90.0% to 79.5% of payout as Gala Health converted twice at $21.81 EPC, but that is diversification within GLP-1 and does not touch the peptide-share question. Zero peptide partners for a 19th consecutive pack. First sizing of peptide commercial intent this run: hims peptides 1,300/mo KD 12 CPC $12.69, compounded peptides 720/mo KD 0 CPC $15.20.
Counter-narrativeA peptide network signed and scaled past 30 percent of payout inside 140 days from a standing start of zero remains the live counter-case, and today's CPCs show the money would be there if one existed.
- morning-sources/first-party-pulse.md 2026-08-12 pack (proprietary, window 2026-08-05 to 2026-08-12, ONE DAY STALE)
- seo-lookup.yml run 31666195673 DataForSEO Labs keyword_overview ($0.0130, 8 keywords)
- 2026-08-14 04:15 UTC · Ra runread brief →92%+0.01· signal 91
Took +0.01 on a mechanism rather than on the funnel. The funnel is flat: payout $3,398 on 464 clicks and 20 conversions, Embody $2,700 at EPC $22.31 and Gala Health $698 at EPC $30.35, zero peptide partners for a 20th consecutive pack with 139 days to horizon. The new evidence is that Lilly on 2026-08-12 sued six named sellers, four of which trade under peptide brand names, and says it has referred 200-plus individuals and entities to the FDA, DOJ, state attorneys general and licensing boards and flagged 14,000-plus listings in 100-plus countries. The population from which a peptide affiliate network would have to be assembled is the population currently being sued and referred. That raises the cost of the counter-narrative without changing the arithmetic that already carries this row.
Counter-narrativeA US telehealth peptide channel opening at scale before December, with Hims as the most likely operator, would put a compliant peptide affiliate surface in reach that the gray-market suits do not touch.
- morning-sources/first-party-pulse.md window 2026-08-06 to 2026-08-13
- https://www.cnbc.com/2026/08/12/lilly-lawsuits-obesity-drug-retatrutide.html
- https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html
- 2026-08-15 04:15 UTC · Ra runread brief →92%0· signal 91
Held. Zero peptide partners in the Katalys table for a 22nd consecutive pack; the single new entrant, bmiMD Personalized Health RX at $150, is a GLP-1 provider and not a peptide vendor. The funnel is $3,649 payout on 659 clicks and 23 conversions, with Embody GLP1 alone at $3,150, or 86 percent of total payout on one partner - the concentration is now the live risk to this forecast and it is a denominator risk, not a peptide-revenue risk. Both peptide news taps returned zero items today, the first fully quiet peptide day in this log's recent run. Numbers restated off the 2026-08-15 pack, which committed eight minutes after this run first read the stale one.
Counter-narrativeA peptide network could be signed and scaled past 30 percent of payout inside 140 days from a standing start, and a glp1picks funnel this concentrated is exactly the denominator that would let a small peptide numerator cross the line.
- morning-sources/first-party-pulse.md 2026-08-15 pack (proprietary, window 2026-08-08 to 2026-08-15, landed 04:16 UTC mid-run and reconciled against the 08-07 to 08-14 pack read at 04:08)
- data/news/2026-08-15.json gnews-compounding and gnews-peptides, both returning 0 items
- 2026-08-16 04:15 UTC · Ra runread brief →92%0· signal 91
Held at 0.92. Read first on the stale 08-08 to 08-15 pack and declined to count the re-read; the 2026-08-16 pack then landed mid-run and was reconciled against, so the hold rests on fresh evidence: nine Katalys partners, all GLP-1, zero peptide partners for a genuine 23rd consecutive pack. Embody concentration eases to 85.1 percent of payout (2,850 of 3,349) on conversions up 24 percent.
Counter-narrativeA Hims peptide launch at scale plus a peptide affiliate programme reaching network underwriting standards would move share fast, and neither needs a filing to happen.
- morning-sources/first-party-pulse.md (2026-08-16 pack, window 2026-08-09 to 2026-08-16, generated 2026-08-16T04:22Z, landed mid-run and reconciled against)
- 2026-08-17 04:25 UTC · Ra runread brief →93%+0.01· signal 92
The Katalys pack is a re-read (_Generated 2026-08-16T04:22), so no confirmation is banked from it under the rule adopted 2026-08-16. The move comes from a source never used on this forecast: the 2026-08-17 GSC snapshot shows bestpeptideforthat, the portfolio's only peptide surface, drew 410 impressions and 0 clicks across 55 pages over 28 days with 5 of 9 reports EMPTY, while glp1picks took 308 clicks in 7 days. Peptide revenue cannot reach 30 percent of affiliate revenue from a property with no organic clicks.
Counter-narrativeA Category-1-equivalent federal outcome plus a US pharma launching an approved peptide product with an affiliate programme could still re-weight the mix before 2026-12-31, and the peptide surface having no traffic today says nothing about December.
- data/gsc/bestpeptideforthat.json
- data/gsc/glp1picks.json
- morning-sources/first-party-pulse.md (re-read, _Generated 2026-08-16T04:22)
- 2026-08-18 04:15 UTC · Ra runread brief →93%0· signal 92
Held at 0.93. The Katalys pack is a re-read under the rule adopted 2026-08-16 and banks nothing. Today's fresh first-party snapshot does: bestpeptideforthat, the portfolio's only peptide surface, took 0 clicks across 55 pages over 28 days with 5 of 9 reports EMPTY, against glp1picks at 1224 clicks on 75533 impressions over the identical window. The 28-day impression figure read 410 yesterday and 300 today as 2026-07-19 rolled out of the window; per the amendment adopted 2026-08-17 that is NOT reported as a decline, because the trailing days of the new window are still backfilling. The click record is 0 on both readings and that is the number this forecast turns on. Peptide revenue cannot reach 30 percent of affiliate revenue from a property with no organic clicks.
Counter-narrativeA Category-1-equivalent federal outcome plus a US pharma or a Hims launching an approved peptide product with an affiliate programme could still re-weight the mix before 2026-12-31, and a peptide surface with no traffic in August says nothing about December.
- data/gsc/bestpeptideforthat.json (gsc-reader service account, generated_at 2026-08-18T03:56:30Z: pages_28d 55 rows, 300 impressions, 0 clicks, window 2026-07-20 to 2026-08-17; queries_28d 44 rows, 88 impressions, 0 clicks; 5 of 9 reports EMPTY)
- data/gsc/glp1picks.json (generated_at 2026-08-18T03:56:26Z: pages_28d 250 rows, 75533 impressions, 1224 clicks; 9 of 9 reports OK)
- morning-sources/first-party-pulse.md (_Generated 2026-08-17T04:28, re-read, banks no confirmation)
- 2026-08-19 04:15 UTC · Ra runread brief →93%0· signal 93
Held at 0.93 on a fresh first-party snapshot that re-confirms rather than adds. bestpeptideforthat, the portfolio's only peptide surface, took 0 clicks across 52 pages over 28 days; its entire strike zone is 5 queries at 1 impression apiece, which is not a ranking problem but an absence of arriving demand. glp1picks took 1237 clicks on 76094 impressions over the identical window. The Katalys pack is a re-read under the rule adopted 2026-08-16 and banks nothing. Impressions read 300 on 08-18 and 181 today as 2026-07-20 rolled out of the window; per the amendment adopted 2026-08-17 that is NOT reported as a decline, because the trailing days of the new window are still backfilling, and clicks are 0 on both readings, which is the number this row turns on. Cross-forecast note: today's FTC action against Hims marginally STRENGTHENS this row, because Hims is the single most likely peptide-affiliate entrant before December and it is now defending a federal consumer-protection complaint.
Counter-narrativeA Category-1-equivalent federal outcome plus a US pharma or a Hims launching an approved peptide product with an affiliate programme could still re-weight the mix before 2026-12-31, and a peptide surface with no traffic in August says nothing about December.
- data/gsc/bestpeptideforthat.json (gsc-reader service account, generated_at 2026-08-19T03:57:46Z: pages_28d 52 rows, 181 impressions, 0 clicks, window 2026-07-21 to 2026-08-18; strike_zone_28d 5 rows, every one at exactly 1 impression and 0 clicks; 5 of 9 reports EMPTY)
- data/gsc/glp1picks.json (generated_at 2026-08-19T03:57:40Z: pages_28d 250 rows, 76094 impressions, 1237 clicks, 9 of 9 reports OK, identical window)
- morning-sources/first-party-pulse.md (_Generated 2026-08-18T04:21:31, re-read, banks no confirmation)
- 2026-08-20 04:15 UTC · Ra runread brief →93%0· signal 94
Third property with measurable clicks is glp1pets, and it is not the peptide one. bestpeptideforthat is at 0 clicks on 51 pages for a 28-day window that now excludes the older impressions - 181 down to 133 as 07-21 rolled out, which is window roll and not decay. glp1picks added 15 clicks and 353 impressions day over day. Nothing about the revenue mix moved; this is confirmation, and it banks nothing new.
Counter-narrativeA forecast held at 0.93 for weeks on the same instrument is a forecast that has stopped being tested; the honest falsifier is a peptide affiliate program signing, which no Search Console report can see.
- data/gsc/bestpeptideforthat.json (gsc-reader service account, generated_at 2026-08-20T03:57:04Z: pages_28d 51 rows, 133 impressions, 0 clicks, window 2026-07-22 to 2026-08-19; strike_zone_28d 4 rows at 4 impressions total; pages_7d and new_queries_7d both EMPTY; 5 of 9 reports EMPTY)
- data/gsc/glp1picks.json (generated_at 2026-08-20T03:57:00Z: pages_28d 1155 rows, 76447 impressions, 1252 clicks, 9 of 9 reports OK, identical window)
- data/gsc/glp1pets.json (generated_at 2026-08-20T03:57:06Z: 12 pages, 1737 impressions, 11 clicks 28d; 5 clicks in the 7 days to 08-19)
- 2026-08-21 04:15 UTC · Ra runread brief →93%0· signal 94
Holds 0.93 on a fresh snapshot rather than a re-read. bestpeptideforthat, the portfolio's only peptide surface, took 0 clicks across 44 pages on 91 impressions over 28 days, with 5 of 9 reports EMPTY; glp1picks took 1,269 clicks on 77,082 impressions over the same window and 309 clicks in the last 7 days. Page and impression counts fell from 51/133 as 07-22 and 07-23 rolled out of the window, which is window roll and per the 2026-08-18 amendment is not reported as decay - the number this forecast turns on is clicks, and it is 0 for a 25th consecutive reading. The Katalys pack carries _Generated 2026-08-20 and is a re-read under the 2026-08-16 rule, so it banks no confirmation. No move: the mechanism is CPA arithmetic and nothing in today's evidence touches it.
Counter-narrativeA single Katalys peptide partner signing at GLP-1-class CPA would move the ratio faster than organic traffic ever could, and the payout table is nine to ten partners deep, so one addition is not a remote event.
- data/gsc/bestpeptideforthat.json snapshot 2026-08-21T03:58:50Z, gsc-reader service account, 28d window 2026-07-23 to 2026-08-20
- data/gsc/glp1picks.json snapshot 2026-08-21T03:58:47Z
- morning-sources/first-party-pulse.md _Generated 2026-08-20T04:23 (re-read, banks nothing)
- 2026-08-22 04:15 UTC · Ra runread brief →93%0· signal 94
Holds. Clicks are 0 for a 26th consecutive reading on the portfolio's only peptide surface. Pages and impressions read 48 and 88 against yesterday's 51 and 133 as 2026-07-23 rolled out of the window - window roll, not decay, per the 2026-08-17 amendment, and clicks are 0 on both readings. The discrete falsifier was queried rather than restated as prose, per the 2026-08-02 evolution entry.
Counter-narrativeA single Katalys peptide partner signing at GLP-1-class CPA would move the ratio faster than organic traffic ever could, and Hims, the likeliest entrant, is now absorbing a federal complaint and a payment-processor penalty at once.
- data/gsc/bestpeptideforthat.json (gsc-reader service account, generated_at 2026-08-22T03:54:25Z: pages_28d 48 rows, 88 impressions, 0 clicks, window 2026-07-24 to 2026-08-21; strike_zone_28d 1 row at 1 impression; 4 of 9 reports EMPTY)
- data/gsc/glp1picks.json (generated_at 2026-08-22T03:54:21Z: pages_28d 250 rows, 76,913 impressions, 1,293 clicks, 9 of 9 OK, identical window)
- discrete falsifier queried explicitly this run - WebSearch for a peptide telehealth platform reaching affiliate-network standards, negative: Precision Peptide Co still shows LegitScript plus a retail DTC site and no affiliate programme, one new unverified name surfaced (Live Vital, positioning as a white-market BPC-157 route)
- morning-sources/first-party-pulse.md _Generated 2026-08-21T04:25 (re-read, banks nothing)
- 2026-08-23 04:15 UTC · Ra runread brief →88%-0.05· signal 95
First genuine test of this row in 27 readings, and it cuts against it. The forecast rests on peptide affiliate CPA being 10 to 30 times below GLP-1 affiliate CPA because peptide vendors pay 10 to 20 percent on an 80 to 200 dollar order. Two of the nine partners in our own Katalys table are ranked national peptide telehealth programs on a comparison page updated 2026-08-20: Bodybuilding Health+, whose Katalys programme is literally named GLP-1 & Longevity and which took the tables second-highest EPC at 133.33 on a single 400-dollar conversion, and Strut Health at 15 clicks and 0 conversions. Bodybuilding.com own store, read at source, carries a Peptides category and a BB HEALTH+ section. So the peptide-versus-GLP-1 revenue boundary this forecast assumes is clean is not clean inside our own payout table, and the bundled-subscription model at 139 dollars a month on twelve-month terms is not the low-CPA vendor economics the row was priced against. What CANNOT be established from here and is the reason the cut is 0.05 rather than 0.15: no evidence attributes that 400 dollars to a peptide rather than a GLP-1 purchase, and Katalys reports at programme level. Separately unchanged: bestpeptideforthat took 0 clicks across 25 pages on 51 impressions, a 27th consecutive zero, and 48/88 to 25/51 is 07-24 rolling out of the window rather than decay per the 2026-08-17 amendment.
Counter-narrativeThe arithmetic has not moved: a bundled subscription is still one payout line and peptide revenue still has to clear 30 percent of the whole affiliate book in 130 days, which one 400-dollar conversion does not begin to do.
- https://healingmaps.com/peptide-telehealth/ (agent-fetch run 32617238174, HTTP 200, 1227136 bytes, updated 2026-08-20: Bodybuilding Health+ ranked 4.4/5 as Sermorelin + NAD+ + GLP-1, the mens stack, from 139 dollars a month on twelve-month bundles; Strut Health ranked 4.5/5 for oral Sermorelin from about 99 dollars)
- https://shop.bodybuilding.com/blogs/bb-health/get-to-know-peptide-bpc-157 (agent-fetch run 32617238174, HTTP 200, 325177 bytes, article dated June 08 2026: the store navigation carries a Peptides category under Vitamins and Supplements and a BB HEALTH+ section)
- morning-sources/first-party-pulse.md window 2026-08-15 to 2026-08-22 (Katalys: Bodybuilding.com GLP-1 & Longevity 3 clicks, 1 conversion, 400 dollars payout, EPC 133.33; Strut Health 15 clicks, 0 conversions)
- data/gsc/bestpeptideforthat.json (gsc-reader service account, generated_at 2026-08-23T03:58:51Z: pages_28d 25 rows, 51 impressions, 0 clicks, window 2026-07-25 to 2026-08-22; strike_zone_28d 0 rows; 5 of 9 reports EMPTY)
- data/gsc/glp1picks.json (generated_at 2026-08-23T03:58:48Z: pages_28d 77110 impressions, 1295 clicks, 9 of 9 OK, identical window)
- 2026-08-24 04:15 UTC · Ra runread brief →88%0· signal 95
Holds. No new first-party payout data - the morning pack did not regenerate today, so the 08-23 Katalys table is a re-read and not a second observation. The zero-click record on our own peptide surface lengthens to 28 days and still measures our distribution, not the category's economics.
Counter-narrativeTwo of the nine partners in the Katalys table are third-party-ranked national peptide telehealth programmes selling 12-month bundles at GLP-1 prices, and Katalys reports at programme level so that revenue cannot be split.
- data/gsc/bestpeptideforthat.json (gsc-reader service account, generated_at 2026-08-24T04:03:43Z, window 2026-07-26 to 2026-08-23: pages_28d 25 rows 47 impressions 0 clicks, queries_28d 2 rows 2 impressions, strike_zone_28d EMPTY, queries_7d EMPTY, new_queries_7d EMPTY, 4 of 9 reports OK) - 28th consecutive zero-click day
- data/gsc/glp1picks.json (generated_at 2026-08-24T04:03:38Z, 9 of 9 OK, pages_28d 250 rows 77,292 impressions 1,290 clicks, identical window)
- morning-sources/first-party-pulse.md carries _Aggregated: 2026-08-23T04:24_ and is a RE-READ, no new Katalys payout data this run
- seo-lookup run 32689073498 (8 keywords, location 2840, $0.0128) sizes a 60,810/mo melanotan demand cluster - demand-side only, no revenue attribution
- 2026-08-25 04:20 UTC · Ra runread brief →90%+0.02· signal 96
Up 0.02 on composition, not on level. The new first-party pack shows 96 percent of the week's affiliate payout coming from one GLP-1 telehealth partner and no peptide partner present at all, which is the source pack's own named test for this row and it points one way. The -52 percent conversion and -58 percent payout figures are NOT priced: Katalys approves and reverses conversions after the fact, so the trailing days of a window ending yesterday are still settling, and the same discipline the 2026-08-17 amendment applied to trailing GSC days applies here. What is not backfill-sensitive is which partners exist in the account, and no peptide partner does. The counter-case genuinely strengthened too - a shrinking denominator is the one mechanism that could carry this forecast to FALSE without any peptide revenue growth - which is why the move is 0.02 and not more.
Counter-narrativeTwo of the nine Katalys partners are third-party-ranked national peptide telehealth programmes selling twelve-month bundles at GLP-1 prices and Katalys reports at programme level, so that revenue cannot be split; and a denominator that halves in a week makes a 30 percent share arithmetically easier to reach, not harder.
- morning-sources/first-party-pulse.md carrying _Generated: 2026-08-24T04:32:05Z_ - GENUINELY NEW this run, since the 2026-08-24 brief read the 08-23T04:24 pack and the 08-24 pack landed 17 minutes after that run finished
- Katalys window 2026-08-17 to 2026-08-24: 867 clicks (+2%), 10 conversions (-52%), $1,400 payout against $3,349 prior, of which Embody GLP1 alone took $1,350 on 119 clicks at $11.34 EPC - 96 percent of the week's payout from a single GLP-1 telehealth partner
- ZERO peptide-DTC partners appear anywhere in the nine-row partner table, which is the exact check the source pack names for this forecast_id
- data/gsc/bestpeptideforthat.json generated_at 2026-08-24T04:03:43Z is a RE-READ (yesterday's run cited the same stamp) and banks nothing; the 08-25 GSC snapshot never ran, run 32807113768 FAILED at 03:57 UTC
- 2026-08-26 04:20 UTC · Ra runread brief →90%0· signal 93
Holds. No new first-party pack: morning-sources.yml last ran 2026-08-24T04:32Z and every run since has failed. The 08-25 entry moved this row +0.02 on composition; that evidence is now a re-read and banks nothing. Signal strength 96 -> 93 for staleness alone, not for any change in the world. Two consecutive days without a payout table is the first thing that would make this row genuinely unmeasured rather than merely unchanged.
Counter-narrativeA halving denominator carries this row to FALSE with no peptide revenue growth at all, and the payout window that produced the 96%-from-one-GLP-1-partner reading is still settling.
- morning-sources/first-party-pulse.md _Generated: 2026-08-24T04:32:05Z_ (RE-READ, no new pack since; morning-sources.yml has not run since the outage began)
- 2026-08-27 04:35 UTC · Ra runread brief →90%0· signal 94
Holds. The GSC half of the evidence base is genuinely new for the first time in three days because the local bridge produced it while the runners stayed dead, and it says the same thing at a fresh window end: our peptide surface took 0 clicks on 49 impressions in the 28 days to 2026-08-25 while the GLP-1 surface took 1,318 on 77,512 over the identical window. That is a 1,318-to-0 split inside one portfolio, and it is the cleanest statement of this forecast's mechanism yet recorded. It still measures our distribution rather than the category's economics, which is why it confirms rather than moves. Signal strength 93 to 94 on the fresh observation. The Katalys payout table is now three days stale and remains the one input that could make this row unmeasured rather than merely unchanged.
Counter-narrativeA halving denominator carries this row to FALSE with no peptide revenue growth at all, and two of the nine Katalys partners are national peptide telehealth programmes selling twelve-month bundles at GLP-1 prices that Katalys reports only at programme level.
- data/gsc/bestpeptideforthat.json generated_at 2026-08-26T13:30:56Z - GENUINELY NEW, produced by scripts/bridge-local.sh rather than gsc-snapshot.yml, which is quota-dead; window 2026-07-28 to 2026-08-25, 4 of 9 reports OK, pages_28d 23 rows carrying 0 clicks on 49 impressions, queries_28d a single row 'follistatin peptide reddit' at position 61.0, strike_zone_28d EMPTY
- data/gsc/glp1picks.json generated_at 2026-08-26T13:30:48Z, 9 of 9 OK, identical window, pages_28d 1,210 rows carrying 1,318 clicks on 77,512 impressions
- morning-sources/first-party-pulse.md still _Generated: 2026-08-24T04:32:05Z_ - THIRD consecutive re-read, no Katalys payout table since 08-24, morning-sources.yml has not run since the quota exhaustion
- 2026-08-28 04:40 UTC · Ra runread brief →90%0· signal 95
Holds. The 28-day window to 2026-08-26 gives glp1picks 1,265 clicks on 74,857 impressions and bestpeptideforthat 0 clicks on 48 impressions across 23 pages, with a single query row, 'follistatin peptide reddit' at position 61. That is the second consecutive independent window showing the same shape and it confirms rather than moves: it measures our distribution, not the category's economics. Correction to my own first read this run - I initially scored these files as all-zero because I looked for rows at reports.<key>.rows when they live at reports.<key>.payload.rows, and checked before writing anything down.
Counter-narrativeA halving denominator carries this row to FALSE with no peptide revenue growth at all, and the Katalys payout table is now four days stale, which is the one input that would make this genuinely unmeasured rather than merely unchanged.
- data/gsc/glp1picks.json and data/gsc/bestpeptideforthat.json, both generated_at 2026-08-27T06:53Z by scripts/bridge-local.sh, window 2026-07-29 to 2026-08-26 - GENUINELY NEW and a second independent window after yesterday's
- morning-sources/first-party-pulse.md _Generated: 2026-08-24T04:32:05Z_ (RE-READ, fourth consecutive day, banks nothing)
- 2026-08-29 04:30 UTC · Ra runread brief →90%0· signal 96
Holds. Third consecutive independent GSC window at the same shape and the shape is stable: the peptide property has 38 impressions and no clicks against glp1picks' 75,111 and 1,280. That measures OUR distribution, not the category's economics, and it is the wrong instrument for this row - which is the standing complaint, not a new one. The falsifier ran and was negative for the second run in a row. The one input that would make this row genuinely measured rather than merely unchanged is the Katalys payout table, five days stale.
Counter-narrativeA halving denominator would carry this row to FALSE with no peptide revenue growth at all, and the Katalys payout table has been stale since 2026-08-24, so 'unchanged' here may be 'unmeasured' wearing the same clothes.
- data/gsc/glp1picks.json and data/gsc/bestpeptideforthat.json, both generated_at 2026-08-28T07:04Z by scripts/bridge-local.sh - GENUINELY NEW and a THIRD independent window; glp1picks 28d 1,280 clicks on 75,111 impressions, bestpeptideforthat 28d 0 clicks on 38 impressions across 20 pages
- Falsifier queried explicitly per the 2026-08-02 discrete-event rule - NEGATIVE: no affiliate programme surfaced for The Precision Peptide Company or any 503A peptide platform; every return is the already-logged 2026-06-23 LegitScript certification and 2026-07-07 nationwide DTC launch
- morning-sources/first-party-pulse.md _Generated: 2026-08-24T04:32:05Z_ (RE-READ, fifth consecutive day, banks nothing)
- 2026-08-30 04:30 UTC · Ra runread brief →90%0· signal 96
Holds. The falsifier's negative is now weaker than it looks and that is the finding: the argument moves from 'no peptide affiliate programmes exist' to 'programmes exist, a competitor is already earning on them, and we have no traffic to monetise with one'. Same 0.90, more fragile mechanism, and the row becomes genuinely live rather than arithmetic the moment bestpeptideforthat's traffic turns. Window discipline: 19 impressions today against 38 yesterday is two different trailing 28-day windows and is NOT a collapse - this repo's own most recent commit says trailing windows invent collapses, and I am not going to invent one.
Counter-narrativeThe row is arithmetic on a denominator we have stopped measuring - the Katalys payout table has been stale since 2026-08-24 - so 'unchanged' may be 'unmeasured' wearing the same clothes, and a collapsing GLP-1 denominator would carry it FALSE with no peptide growth at all.
- Falsifier queried per the 2026-08-02 discrete-event rule - the result changes the ARGUMENT without changing the number: healingmaps.com 'The 4 Best Peptide Telehealth Programs of 2026', https://healingmaps.com/peptide-telehealth/, discloses affiliate relationships with the programmes it features and that it may earn a commission on sign-ups, so peptide-telehealth affiliate revenue demonstrably exists in the market
- data/gsc/bestpeptideforthat.json generated_at 2026-08-29T07:34:14Z, FOURTH independent window: 0 clicks on 19 impressions across 8 URLs, 28d; data/gsc/glp1picks.json same run: 1,287 clicks on 75,141 impressions
- kalkine.ca 2026-08-27 via data/news/2026-08-29.json gnews-compounding: Hydreight Technologies Q2, peptide healthcare platform, 449% revenue growth
- 2026-08-31 04:30 UTC · Ra runread brief →90%0· signal 96
Quiet. Nothing today bears on The Compound's own affiliate mix, which is what this forecast resolves on. The Rebody item is a newswire release and is logged as an argument to watch rather than a number to move; per the order-defect histogram, PRESS-RELEASE material read as a primary source is a live failure mode of mine. Hold 0.90.
Counter-narrativeA competitor bundling peptides with TRT and GLP-1 in one subscription is evidence that the three-category bundle is commercially viable, which is the shape of the world in which peptide revenue share rises faster than the arithmetic predicts.
- Rebody Health 'Combines Peptide, TRT, and GLP-1 Care in One Plan', openPR 2026-08-29 via data/news/2026-08-29.json gnews-trt SECONDARY (PRESS-RELEASE tier, treated as promotional copy and not as a market fact)
- 2026-09-01 04:30 UTC · Ra runread brief →90%0· signal 96
Holds. Nothing today touches The Compound's own affiliate mix, which is what this row resolves on. The Peptides TIL launch is newswire copy and is logged as an argument to watch, not a number to move, per the PRESS-RELEASE lesson in the defect histogram. Note the standing fragility: the Katalys payout denominator has been stale since 2026-08-24, so 'unchanged' is partly 'unmeasured'. Actions recovered today, so that measurement is restorable tomorrow.
Counter-narrativeA competitor launching a peptide content site whose stated surface includes where-to-buy is evidence that peptide affiliate monetisation is being actively built out by others, which is the shape of the world in which peptide revenue share rises faster than the arithmetic assumes.
- data/news/2026-08-30.json gnews-compounding
- OCNJ Daily 2026-08-29 and FinancialContent 2026-08-29 (Peptides TIL launch, newswire)
- Katalys payout table stale since 2026-08-24
- 2026-09-02 04:15 UTC · Ra runread brief →90%0· signal 96
Quiet, and genuinely so. Nothing today touches The Compound's own affiliate mix, which is the only thing this row resolves on. Both peptide-commerce items are newswire copy and are logged as arguments to watch rather than numbers to move, per the PRESS-RELEASE lesson standing in the defect histogram. Standing fragility unchanged: the Katalys payout denominator is stale, so the resolution arithmetic rests on a file nobody has refreshed.
Counter-narrativePeptide affiliate infrastructure is visibly being built out by others while The Compound has no peptide traffic to monetise, so the forecast could resolve TRUE for the wrong reason: not because peptide affiliate economics stayed weak, but because we never showed up to the category.
- data/news/2026-09-01.json gnews-compounding (LifespanningRx Peptide Explorer launch, EIN News 2026-08-31, newswire)
- data/news/2026-09-01.json gnews-trt (Rebody Health, openPR 2026-08-29, newswire)
- 2026-09-03 05:40 UTC · Ra runread brief →90%0· signal 96
FALSIFIER QUERIED EXPLICITLY AND THE RESULT IS NEGATIVE, which is the discipline the 2026-08-02 Evolution Log entry asked for: this row's falsifier names a discrete checkable event, so it gets a query every run and the negative gets logged rather than restated as prose. Checked this run against the Katalys 7d partner table: nine partners, zero peptide-DTC vendors, and Embody alone is $900 of the $1,250 payout, 72 percent. GLP-1 telehealth is not merely dominant, it is concentrated in one partner. 0.90 holds.
Counter-narrativeA December resolution reads a full-year payout file, not one 7-day window, and a peptide partner could onboard and scale inside the remaining 17 weeks without appearing in today's table.
- morning-sources/first-party-pulse.md, Katalys 7d window 2026-08-26 to 2026-09-02 (payout $1,250, 1,544 clicks, 10 conversions; partner table read row by row)
- 2026-09-04 04:20 UTC · Ra runread brief →90%0· signal 96
Holds. Falsifier queried again and negative: the Katalys 7-day partner table lists nine partners and zero peptide vendors, with Embody at 750 dollars of the 1,100 dollar payout. Deliberately NOT quoting this run's payout decline as a fact - the pulse's window construction under-reports the current period (see section 4), and the Katalys reporting lag is unmeasured, so the direction of that number is unverified even though the zero-peptide-vendors fact is not.
Counter-narrativeA Category 1 rulemaking landing early plus a major US peptide affiliate programme would move this faster than the arithmetic suggests, and neither is visible yet.
- morning-sources/first-party-pulse.md (Katalys 7d, generated 2026-09-03T08:19:03Z)
- 2026-09-05 04:20 UTC · Ra runread brief →90%0· signal 96
Holds. Falsifier queried explicitly and negative for a seventh consecutive run, which is the discipline the 2026-08-02 Evolution Log entry asked for: this row's falsifier names a discrete checkable event, a peptide vendor appearing in the Katalys payout table with non-zero EPC, and the table has nine partners and none of them is one. Deliberately NOT quoting the week-on-week payout decline from $1,550 to $1,400 as a market fact - the pulse's rolling-window construction under-reports the tail and this is a revenue-mix forecast, not a revenue-level one.
Counter-narrativeA December resolution reads a full-year payout file rather than one 7-day window, and a peptide vendor could onboard and scale inside the remaining 16 weeks without appearing in today's table.
- morning-sources/first-party-pulse.md, Katalys 7d window 2026-08-28 to 2026-09-04 (generated 2026-09-04T08:15:11Z; payout $1,400, 862 clicks, 11 conversions; partner table read row by row, nine partners, zero peptide vendors, Embody GLP1 at $1,050 of the $1,400)
- 2026-09-06 04:20 UTC · Ra runread brief →90%0· signal 96
Holds. Falsifier queried explicitly and negative for an eighth consecutive run, which is the discipline the 2026-08-02 Evolution Log entry asked for: the discrete checkable event this row names is a peptide vendor appearing in the Katalys payout table with non-zero EPC, and the table has nine partners and none of them is one. Deliberately NOT quoting this week's payout rise from $1,400 to $1,700 as a market fact, for the same reason last week's fall was not quoted: the pulse's rolling-window construction under-reports the tail, the Katalys reporting lag is unmeasured, and this is a revenue-MIX forecast where the level is irrelevant and the mix is not. The mix fact is window-insensitive and it is the one being cited.
Counter-narrativeA December resolution reads a full-year payout file rather than one 7-day window, and a peptide vendor could onboard and scale inside the remaining 16 weeks without ever appearing in today's table.
- morning-sources/first-party-pulse.md, Katalys 7d window 2026-08-29 to 2026-09-05 (generated 2026-09-05T07:52:37Z; payout $1,700, 791 clicks, 13 conversions; partner table read row by row, nine partners, zero peptide vendors, Embody GLP1 at $1,350 of the $1,700 and SnagRX at $150)
- 2026-09-07 04:11 UTC · Ra runread brief →90%0· signal 96
Holds. Falsifier queried explicitly and negative for a NINTH consecutive run: the discrete checkable event this row names is a peptide vendor appearing in the Katalys payout table with non-zero EPC, and the table has nine partners and none of them is one. Today also puts a live instance under yesterday's Premortem finding rather than leaving it abstract: plexusdx.com is a peptide vendor at nationwide DTC scale selling five prescription peptide programmes, and it is exactly the kind of vendor that could carry peptide revenue through a network Katalys cannot see. I looked for a public affiliate programme at the conventional path and got a redirect to the homepage, which is NOT evidence that no programme exists and is recorded as unverified rather than as a negative. Deliberately NOT quoting this week's payout rise from $1,700 to $1,800 or the 51 percent click fall as market facts: the pulse's rolling-window construction under-reports the tail, and this is a revenue-MIX forecast where the level is irrelevant and the mix is not.
Counter-narrativeA December resolution reads a full-year payout file across every network rather than one 7-day Katalys window, and yesterday's Premortem established that this falsifier is scoped to one network while the forecast is scoped to total Compound affiliate revenue.
- morning-sources/first-party-pulse.md, Katalys 7d window 2026-08-30 to 2026-09-06 (generated 2026-09-06T08:09:03Z; payout $1,800, 866 clicks, 13 conversions; partner table read row by row, nine partners, zero peptide vendors, Embody GLP1 at $1,500 of the $1,800, SnagRX $150, bmiMD $100, Ro.co $50, five partners at zero)
- https://plexusdx.com/pages/affiliates (HTTP 200 but redirected to https://plexusdx.com/, i.e. no affiliate page at that path, agent-fetch run 34082077708, read 2026-09-07)
- 31 Dec 2026 · resolves
107 days remaining. Re-evaluated each dawn by the council.
Sources at creation
- Blueprint revenue modeling; Katalys $260 Found CPA vs peptide vendor 10-20 percent commissions on $80-200 AOV ($8-40 per sale); BPC-157 PCAC forecast restricting compounding distribution
Sources cited in subsequent Ra runs appear in each trajectory entry above.
Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.